Old Web
English
Sign In
Acemap
>
authorDetail
>
Vicki Rimkunas
Vicki Rimkunas
Pathology
Medicine
Antagonist
Cancer research
Endocrine system
3
Papers
4
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase I dose escalation of H3B-6545, a first-in-class highly Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer (HR+ BC).
2019
Journal of Clinical Oncology
Erika Paige Hamilton
Elizabeth Claire Dees
Judy Sing-Zan Wang
Amy Kim
Manav Korpal
Vicki Rimkunas
Nathalie Rioux
Joanne Schindler
Dejan Juric
Show All
Source
Cite
Save
Citations (4)
Molecular characterization and monitoring of patient ctDNA in phase I study of H3B-6545 in ER+ MBC.
2019
Journal of Clinical Oncology
Vicki Rimkunas
Zhaojie Zhang
Erika Paige Hamilton
Dejan Juric
Judy Sing-Zan Wang
Elizabeth Claire Dees
Lihua Yu
Ping Zhu
Huilan Yao
Laura Ankstitus
Subhasree Das
Manav Korpal
Peter C. Smith
Joanne Schindler
Pavan Kumar
Show All
Source
Cite
Save
Citations (0)
H3B-6527 clinical biomarker assay development and characterization of HCC patient samples.
2019
Journal of Clinical Oncology
Pavan Kumar
Vicki Rimkunas
Kun Yu
Zhaojie Zhang
Crystal Mackenzie
Joanne Schindler
Peter C. Smith
Ping Zhu
Anand Selvaraj
Lihua Yu
Subhasree Das
Jaya Julie Joshi
Show All
Source
Cite
Save
Citations (0)
1